FY

INNOVIZ TECHNOLOGIES LTD. (NASDAQ: INVZ) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Innoviz Technologies Ltd.

Retrieved on: 
Monday, April 1, 2024
FY, Volkswagen, District court, News, Complaint, Action Replay, BMW, GAAP, Court, Advertising, Security (finance)

If you purchased or acquired Innoviz securities, and/or would like to discuss your legal rights and options please visit Innoviz Technologies Ltd.

Key Points: 
  • If you purchased or acquired Innoviz securities, and/or would like to discuss your legal rights and options please visit Innoviz Technologies Ltd.
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 14, 2024.
  • If you purchased or acquired Innoviz securities, and/or would like to discuss your legal rights and options please visit Innoviz Technologies Ltd.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Innoviz Technologies Ltd. of Class Action Lawsuit and Upcoming Deadlines – INVZ

Retrieved on: 
Sunday, March 31, 2024
FY, Original equipment manufacturer, Volkswagen, District court, Perception, Aptiv, News, Ext, Complaint, BMW, GAAP, Pomerantz, Action Replay, Court, Person, Mail

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Plug Power Inc. of Class Action Lawsuit and Upcoming Deadlines – PLUG

Retrieved on: 
Sunday, March 31, 2024
Prior, Pressure, Citigroup, Growth, FY, District court, Defendant, News, Ext, Integral, Alpha, Complaint, Morgan Stanley, Plant, GAAP, Pomerantz, Action Replay, Probability, Court, Economics, Person, Cryptocurrency

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Plug Power Inc. (“Plug” or the “Company”) (NASDAQ: PLUG) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Plug Power Inc. (“Plug” or the “Company”) (NASDAQ: PLUG) and certain officers.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Plug offers its products to retail-distribution and manufacturing businesses through a direct product sales force, original equipment manufacturers, and dealer networks.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman

Retrieved on: 
Friday, March 29, 2024
Research, Communication, FY, GRFS, SAN, Person, Disclosure, American depositary receipt, Annual report, Hagens Berman

SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
  • Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
    Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
  • Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
  • 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.

INVZ INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Innoviz Technologies Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, March 29, 2024
Original equipment manufacturer, FY, Volkswagen, Perception, Aptiv, News, Complaint, BMW, Court, Person, Cryptocurrency

Innoviz designs and manufactures solid-state light detection and ranging, or “LiDAR”, sensors and develops perception software that purportedly enables the mass production of autonomous vehicles.

Key Points: 
  • Innoviz designs and manufactures solid-state light detection and ranging, or “LiDAR”, sensors and develops perception software that purportedly enables the mass production of autonomous vehicles.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Innoviz you have until May 14, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

Verde Announces Q4 and FY 2023 Results

Retrieved on: 
Thursday, March 28, 2024
Potassium chloride, Farmer, Central bank, FY, CNM, Risk, Global warming potential, History, ECLS, Carbon, Carbon dioxide, Fertilizer, Depreciation, Weather

SINGAPORE, March 28, 2024 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) announces its financial results for the full year ended December 31, 2023 (“FY 2023”) and the fourth quarter 2023 (“Q4 2023”), as audited by Ernst & Young (“EY”). The FY 2023 audited results were consistent with the interim results announced by the Company on January 26, 2024:

Key Points: 
  • Verde's revenue amounted to $37.9 million in FY 2023, a 53% decrease compared to the previous year, when potash prices reached record levels.
  • The Company reported a net loss of $6.0 million in FY 2023, compared to a net profit of $17.8 million in FY 2022.
  • Canadian dollar devaluated by 7% versus Brazilian Real in FY 2023 compared to FY 2022.
  • The Company will host a conference call on Tuesday, April 02, 2024, at 10:00 am Eastern Time, to discuss Q4 and FY 2023 results and provide an update.

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Wednesday, March 27, 2024
De novo, DFU, Diabetic foot ulcer, Certification, Burn, Government, Development, FY, MDAI, Patient, Research, History, Artificial intelligence, Classification, Sale, Standard of care, Human services, Research and development, Wound healing, Trial of the century, Clinical trial, ASPR, ISO, FDA, Administration, Food, Pharmaceutical industry

DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.

Key Points: 
  • DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
  • “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer.
  • “
    In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million.
  • All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.

INVZ Class Action Alert: Robbins LLP Remind Stockholders of Lead Plaintiff Deadline in Innoviz Technologies Ltd. Class Action

Retrieved on: 
Tuesday, March 26, 2024
FY, SAN, Perception, News, LLP, Complaint, Tacit assumption, Person, Cryptocurrency

For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • The Allegations: Robbins LLP is Investigating the Allegations that Innoviz Technologies Ltd.
  • What Now: You may be eligible to participate in the class action against Innoviz Technologies Ltd. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 14, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Amendment - 2023 Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Financial statement, Environmental impact assessment, Icelandic, Vein, Government, Mining, Growth, Fundraising, Bed, OMX, FY, Nanoq, ESG, Webcast, Corporation, Gold, Copper, Q4, Rehabilitation, Social impact assessment, SIA, Capital market, REE, Niobium, IOCG, Workforce, Unit, EIA, AIM, Nasdaq Iceland, Engineering, Person, Rare-earth element

Amendments have been made to the ‘2023 Full Year Financial Results’ announcement released on 26 March 2024 at 07:00 in the Financial Results table.

Key Points: 
  • Amendments have been made to the ‘2023 Full Year Financial Results’ announcement released on 26 March 2024 at 07:00 in the Financial Results table.
  • “We experienced some operational and procurement delays towards the end of 2023 due to adverse weather conditions, which continued into the start of 2024.
  • Amaroq will continue to review the results of the detailed geophysical programme conducted over the Kobberminebugt licence in 2023.
  • The following selected financial data is extracted from the Financial Statements for the three months ended December 31, 2023.